Learn more about creating an effective co-crystal screening protocol
Solid form selection and development is one of the key aspects of pharmaceutical research, as over 90% of all APIs on the market are approved as solid formulations. These require a thorough understanding of the solid form landscape of the API and of the crystallization process to be reliably controlled towards the desired solid form. By choosing the appropriate polymorph, salt or co-crystal of the given API, the formulation chemist can tune the physico-chemical properties of the compound, and in turn its therapeutic profile.
This application note shows that an effective co-crystal screening protocol can be defined, using the Crystal16 instrument.
Content overview:
- Why co-crystals?
- Co-crystal screening state-of-the-art
- The case study of Febuxostat and its co-crystal screening with p-toluenesulfonic acid
- Using an AI graph algorithm for co-crystal prediction
- Co-crystal experimental screening
- Method A: Cooling Crystallization
- Method B: Slurry Crystallization
- Conclusions
